Linzagolix, sold under the brand name Yselty, is a medication used in the treatment of uterine fibroids.

[1][5][9] Linzagolix is indicated for treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

[6][10] In clinical studies, linzagolix fully suppressed estradiol levels (median <20 pg/mL) in women at a dosage of 200 mg/day, whereas partial suppression of estradiol levels (median 20–60 pg/mL) occurred at a dosage 100 mg/day.

[6] The elimination half-life of linzagolix with repeated administration is approximately 15 hours.

[11] The applicant for this medicinal product is ObsEva Ireland Ltd.[11] Linzagolix was approved for medical use in the European Union in June 2022.